Avalo Total Assets from 2010 to 2024

AVTX Stock

USD 9.23 0.12 1.32%

Avalo Therapeutics Total Assets yearly trend continues to be fairly stable with very little volatility. Total Assets are likely to outpace its year average in 2024. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2014-12-31

Previous Quarter

108.3 M

Current Value

98.5 M

Quarterly Volatility

31.2 M

Yuan Drop

Covid

Check Avalo Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Avalo Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 150.1 K, Interest Expense of 5.6 M or Selling General Administrative of 11.9 M, as well as many indicators such as Price To Sales Ratio of 1.25, Dividend Yield of 0.0 or PTB Ratio of 0.33. Avalo financial statements analysis is a perfect complement when working with Avalo Therapeutics Valuation or Volatility modules.

Check out the analysis of Avalo Therapeutics Correlation against competitors.

For more information on how to buy Avalo Stock please use our How to Invest in Avalo Therapeutics guide.

Latest Avalo Therapeutics' Total Assets Growth Pattern

Below is the plot of the Total Assets of Avalo Therapeutics over the last few years. Total assets refers to the total amount of Avalo Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Avalo Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Avalo Therapeutics' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Avalo Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 20.99 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Avalo Total Assets Regression Statistics

	Arithmetic Mean	28,341,489
	Geometric Mean	18,507,186
	Coefficient Of Variation	84.86
	Mean Deviation	19,425,683
	Median	21,658,000
	Standard Deviation	24,051,449
	Sample Variance	578.5T
	Range	75.1M
	R-Value	0.63
	Mean Square Error	374.8T
	R-Squared	0.40
	Significance	0.01
	Slope	3,394,737
	Total Sum of Squares	8098.6T

Avalo Total Assets History

	2024	37.3 M
	2023	21 M
	2022	33.4 M
	2021	80.2 M
	2020	43.8 M
	2019	36.1 M
	2018	70.3 M

Other Fundumenentals of Avalo Therapeutics

Intangibles To Total Assets

Avalo Therapeutics Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Common Stock	Current Deferred Revenue	Short Term Debt	Net Receivables	Net Tangible Assets	Good Will	Net Invested Capital	Net Working Capital	Intangible Assets	Property Plant Equipment	Long Term Debt	Short Long Term Debt	Capital Stock	Capital Surpluse	Deferred Long Term Liab
Total Assets		0.78	-0.27	-0.48	0.45	0.57	0.81	0.21	0.63	-0.3	0.83	0.31	0.21	0.38	0.58	-0.25	0.55	0.54	0.45	0.42	-0.06	-0.06
Total Stockholder Equity	0.78		-0.38	-0.35	0.15	-0.04	0.57	0.4	0.46	-0.46	0.66	0.33	0.02	0.18	0.42	-0.26	0.4	0.55	0.42	0.3	-0.11	-0.11
Net Debt	-0.27	-0.38		0.18	-0.18	0.07	-0.62	0.09	-0.77	0.42	0.13	-0.42	0.2	-0.39	-0.75	0.39	-0.26	-0.58	-0.3	-0.61	0.07	0.07
Retained Earnings	-0.48	-0.35	0.18		-0.15	-0.19	-0.37	0.15	-0.24	0.01	-0.1	0.52	0.6	0.41	-0.37	0.81	-0.93	-0.22	-0.84	0.27	0.63	0.63
Accounts Payable	0.45	0.15	-0.18	-0.15		0.61	0.63	-0.06	0.65	0.17	0.41	0.42	0.48	0.44	0.54	-0.33	0.39	0.64	0.43	0.63	0.51	0.51
Total Liab	0.57	-0.04	0.07	-0.19	0.61		0.6	-0.15	0.45	0.17	0.53	0.19	0.45	0.49	0.39	0.03	0.32	0.18	0.16	0.39	0.29	0.29
Total Current Assets	0.81	0.57	-0.62	-0.37	0.63	0.6		-0.03	0.87	-0.18	0.55	0.47	0.24	0.62	0.86	-0.35	0.54	0.69	0.47	0.72	0.18	0.18
Common Stock	0.21	0.4	0.09	0.15	-0.06	-0.15	-0.03		0.01	-0.14	0.22	0.06	0.07	0.08	-0.05	0.15	-0.2	-0.09	-0.19	0.05	0.11	0.11
Current Deferred Revenue	0.63	0.46	-0.77	-0.24	0.65	0.45	0.87	0.01		-0.32	0.33	0.59	0.2	0.66	0.88	-0.32	0.4	0.72	0.38	0.84	0.21	0.21
Short Term Debt	-0.3	-0.46	0.42	0.01	0.17	0.17	-0.18	-0.14	-0.32		-0.28	-0.46	0.22	-0.25	-0.43	0.07	-0.07	-0.46	-0.13	-0.32	0.29	0.29
Net Receivables	0.83	0.66	0.13	-0.1	0.41	0.53	0.55	0.22	0.33	-0.28		0.46	0.53	0.41	0.26	0.11	0.24	0.44	0.21	0.37	0.25	0.25
Net Tangible Assets	0.31	0.33	-0.42	0.52	0.42	0.19	0.47	0.06	0.59	-0.46	0.46		0.67	0.81	0.44	0.31	-0.29	0.63	-0.18	0.89	0.62	0.62
Good Will	0.21	0.02	0.2	0.6	0.48	0.45	0.24	0.07	0.2	0.22	0.53	0.67		0.63	-0.06	0.6	-0.45	0.16	-0.42	0.55	0.82	0.82
Net Invested Capital	0.38	0.18	-0.39	0.41	0.44	0.49	0.62	0.08	0.66	-0.25	0.41	0.81	0.63		0.59	0.38	-0.22	0.36	-0.29	0.9	0.58	0.58
Net Working Capital	0.58	0.42	-0.75	-0.37	0.54	0.39	0.86	-0.05	0.88	-0.43	0.26	0.44	-0.06	0.59		-0.49	0.53	0.73	0.49	0.73	-0.01	-0.01
Intangible Assets	-0.25	-0.26	0.39	0.81	-0.33	0.03	-0.35	0.15	-0.32	0.07	0.11	0.31	0.6	0.38	-0.49		-0.85	-0.52	-0.91	0.06	0.45	0.45
Property Plant Equipment	0.55	0.4	-0.26	-0.93	0.39	0.32	0.54	-0.2	0.4	-0.07	0.24	-0.29	-0.45	-0.22	0.53	-0.85		0.45	0.95	-0.03	-0.39	-0.39
Long Term Debt	0.54	0.55	-0.58	-0.22	0.64	0.18	0.69	-0.09	0.72	-0.46	0.44	0.63	0.16	0.36	0.73	-0.52	0.45		0.59	0.68	0.15	0.15
Short Long Term Debt	0.45	0.42	-0.3	-0.84	0.43	0.16	0.47	-0.19	0.38	-0.13	0.21	-0.18	-0.42	-0.29	0.49	-0.91	0.95	0.59		0.01	-0.3	-0.3
Capital Stock	0.42	0.3	-0.61	0.27	0.63	0.39	0.72	0.05	0.84	-0.32	0.37	0.89	0.55	0.9	0.73	0.06	-0.03	0.68	0.01		0.58	0.58
Capital Surpluse	-0.06	-0.11	0.07	0.63	0.51	0.29	0.18	0.11	0.21	0.29	0.25	0.62	0.82	0.58	-0.01	0.45	-0.39	0.15	-0.3	0.58		1.0
Deferred Long Term Liab	-0.06	-0.11	0.07	0.63	0.51	0.29	0.18	0.11	0.21	0.29	0.25	0.62	0.82	0.58	-0.01	0.45	-0.39	0.15	-0.3	0.58	1.0

Click cells to compare fundamentals

About Avalo Therapeutics Financial Statements

Avalo Therapeutics investors use historical fundamental indicators, such as Avalo Therapeutics' Total Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Avalo Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Total Assets	21 M	37.3 M
Intangibles To Total Assets	0.50	0.53

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Avalo Stock Analysis

When running Avalo Therapeutics' price analysis, check to measure Avalo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avalo Therapeutics is operating at the current time. Most of Avalo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Avalo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avalo Therapeutics' price. Additionally, you may evaluate how the addition of Avalo Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC